ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report

September 12, 2022 GMT

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sep 12, 2022--

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance ( ESG ) priorities. Contained within the report is the company’s inaugural public benefit report, detailing United Therapeutics’ efforts to meet its public benefit purpose: to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

“Since our founding, we have operated with a patient-driven mission, strong values, and a long-term vision,” said James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics. “We are pleased to share this Corporate Responsibility and Public Benefit Report, which showcases our progress as a responsible and sustainable business committed to advancing the interests of our patients, employees, and communities.”

ADVERTISEMENT

“I and my colleagues on the Board of Directors are very pleased to share this report with our shareholders and other stakeholders,” said Christopher Causey, Chair of the Nominating and Governance Committee of the United Therapeutics Board of Directors. “We are the first publicly traded biotechnology company organized as a public benefit corporation; as such, we are committed to fulfilling our purpose and promise to our patients, our employees, and all of humankind. This report highlights our progress toward our highest aspirations – ultimately doing well while also doing good.”

To meet the growing investor demand for ESG information, United Therapeutics has again aligned our reporting with the leading frameworks and standards used by this community. These include the Global Reporting Initiative ( GRI ), Sustainability Accounting Standards Board ( SASB, now part of the IFRS Foundation), and the Task Force on Climate Related Financial Disclosures ( TCFD ). For the first time this year, we have linked our work to the UN Sustainable Development Goals ( UN SDGs ), which provide a shared blueprint for peace and prosperity for people and the planet now and in the future.

ADVERTISEMENT

Find the full report at corporateresponsibility.unither.com.

United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation ( PBC ). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

ADVERTISEMENT

You can learn more about what it means to be a PBC here: unither.com/PBC.

Forward-looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our planned reporting on ESG matters, our commitment to fulfilling our purpose and promise to our patients, our employees, and all of humankind, our ability to create value and sustain our success in the long-term, and our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 12, 2022 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20220912005088/en/

CONTACT: For Further Information:Catherine Sheehy at (240) 398-3504 (sustainability)

Dewey Steadman at (202) 919-4097 (investors/media)Email:ir@unither.com

ADVERTISEMENT

KEYWORD: NORTH CAROLINA MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ENVIRONMENT ENVIRONMENTAL POLICY PROFESSIONAL SERVICES SUSTAINABILITY PHILANTHROPY BIOTECHNOLOGY PHARMACEUTICAL HEALTH ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) OTHER PHILANTHROPY

SOURCE: United Therapeutics Corporation

Copyright Business Wire 2022.

PUB: 09/12/2022 05:00 PM/DISC: 09/12/2022 05:02 PM

http://www.businesswire.com/news/home/20220912005088/en